Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.
Xeris Biopharma Holdings, Inc. reports news about its commercial biopharmaceutical business, including product revenue, financial guidance and operating updates tied to Recorlev®, Gvoke® and Keveyis®. The company commercializes Recorlev for endogenous Cushing’s syndrome, Gvoke ready-to-use liquid glucagon for severe hypoglycemia and Keveyis for primary periodic paralysis.
Recurring updates also cover development of XP-8121, a Phase 3-ready once-weekly subcutaneous levothyroxine candidate for hypothyroidism, and programs using Xeris’ XeriSol® and XeriJect® technology platforms. Company news includes intellectual property developments for Recorlev, partnership-related revenue, and equity inducement grants under Nasdaq listing rules.
Summary not available.
Summary not available.
Summary not available.
Xeris Biopharma Holdings (NASDAQ: XERS) has received a new patent (US Patent Number 11,590,205) from the U.S. Patent and Trademark Office, covering formulations within its Gvoke® product line for treating hypoglycemia. This patent reinforces Xeris' intellectual property strategy, bolstering its XeriSol™ platform. The company boasts a robust patent portfolio of 178 patents globally, with 33 issued in the U.S., and additional applications pending. The CEO, Paul R. Edick, emphasized the significance of this patent in enhancing the company’s market position. Xeris is committed to developing innovative therapies, with existing products including Gvoke®, Keveyis®, and Recorlev®, and a diverse pipeline aimed at various human diseases.
Xeris Biopharma Holdings (Nasdaq: XERS) has entered a collaboration with Regeneron Pharmaceuticals to utilize its XeriJect™ platform for developing concentrated subcutaneous injections of two undisclosed monoclonal antibodies. The agreement includes an upfront payment and potential milestone payments based on preclinical achievements. Regeneron retains the option to commercially license the Xeris technology and nominate additional molecules for reformulation. XeriJect™ offers ready-to-use, high-drug-loaded suspensions, addressing patient needs in drug delivery. This partnership is a part of Xeris' ongoing collaborations with major biopharmaceutical firms.
Xeris Biopharma Holdings (Nasdaq: XERS) appointed Ricki Fairley to its Board of Directors, expanding the board to nine members as of March 27, 2023. Fairley brings over 35 years of marketing experience, including roles at Johnson & Johnson and Coca-Cola. She is the co-founder and CEO of TOUCH, The Black Breast Cancer Alliance and has a history of advocating for increased participation of Black women in clinical trials. The company's focus remains on developing and commercializing innovative products to enhance patient care.
Xeris Biopharma achieved a record fourth quarter net product revenue of $32.5M, marking a 52% growth compared to Q4 2021. Full-year revenues reached $109.3M, a 38% increase year-over-year on a pro forma basis. The company ended 2022 with $122.0M in cash and achieved $50M in synergies from the Strongbridge acquisition. For 2023, Xeris projects revenues between $135M-$165M and cash utilization from operations of $57M-$77M. The company aims for cash flow breakeven by Q4 2023. Recent collaborations, including with Horizon Therapeutics, further enhance its growth prospects.
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) has announced it will release its fourth-quarter and full-year 2022 financial results on March 8, 2023, before market open. Following this, management will host a conference call and webcast at 8:30 a.m. ET to discuss the outcomes. Xeris focuses on developing innovative biopharmaceutical products, including Gvoke®, Keveyis®, and Recorlev®. The company aims to enhance patient lives through differentiated therapies and has a diverse pipeline leveraging its proprietary formulation sciences, XeriSol™ and XeriJect™.
Xeris Biopharma, Inc. (Nasdaq: XERS) announced its participation in the SVB Securities Global Biopharma Conference 2023, scheduled for February 15, 2023, from 10:40 to 11:10 am ET. Senior management will conduct 1x1 investor meetings and provide a company overview. Investors can access the audio webcast on the company's website. Xeris is focused on developing innovative biopharmaceutical products, including Gvoke® for severe hypoglycemia, Keveyis® for primary periodic paralysis, and Recorlev® for Cushing's syndrome. The company utilizes proprietary formulation platforms, XeriSol™ and XeriJect™, to enhance its product pipeline.
Xeris Biopharma Holdings (Nasdaq: XERS) has received orphan-drug exclusivity for Recorlev® (levoketoconazole) from the FDA, marking it as the first approved treatment for endogenous Cushing’s syndrome. This exclusivity provides Xeris a seven-year market advantage following its December 30, 2021, approval. Recorlev is indicated for adult patients unable to undergo surgery or where surgery has failed. The approval is based on successful Phase 3 trials involving 166 patients, demonstrating significant efficacy in cortisol reduction. Xeris emphasizes its commitment to supporting patients through comprehensive programs like Xeris CareConnection.